Page 6,712«..1020..6,7116,7126,7136,714..6,7206,730..»

Generating dopamine via cell therapy for Parkinson's disease

Posted: Published on July 2nd, 2012

Public release date: 2-Jul-2012 [ | E-mail | Share ] Contact: Sarah Jackson press_releases@the-jci.org Journal of Clinical Investigation In Parkinson's disease, the loss of dopamine-producing cells in the midbrain causes well-characterized motor symptoms. Though embryonic stem cells could potentially be used to replace dopaminergic (DA) neurons in Parkinson's disease patients, such cell therapy options must still overcome technical obstacles before the approach is ready for the clinic. Embryonic stem cell-based transplantation regimens carry a risk of introducing inappropriate cells or even cancer-prone cells. To develop cell purification strategies to minimize these risks, Dr. Lorenza Studer and colleagues at Memorial Sloan Kettering Cancer Center in New York developed three different mouse lines to fluorescently label dopaminergic neurons at early, mid, and late stages of differentiation. Their data suggest that mouse embryonic stem cells induced to the mid stage of neuronal differentiation are best suited for transplantation to replace dopaminergic neurons. Further, their work identified new genes associated with each stage of neuronal differentiation. Their results in the mouse model system help define the differentiation stage and specific attributes of embryonic stem cell-derived, dopamine-generating cells that hold promise for cell therapy applications. ### TITLE: Identification of embryonic stem cellderived midbrain dopaminergic neurons … Continue reading

Posted in Cell Therapy | Comments Off on Generating dopamine via cell therapy for Parkinson's disease

China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2012 Earnings Results and Schedules Conference Call for July 3, 2012

Posted: Published on July 2nd, 2012

HANGZHOU, China--(BUSINESS WIRE)-- China Jo-Jo Drugstores, Inc. (CJJD) (the Company), a retail and wholesale distributor of pharmaceutical and other healthcare products in China, today reported earnings results for the fiscal year ended March 31, 2012. The Company will hold a conference on Tuesday, July 3, 2012, at 8:00 a.m. Eastern Time. Please see below for dial-in information. Mr. Lei Liu, the Companys Chairman and CEO, stated, During fiscal year 2012, we faced a continually challenging regulatory environment as more over-the-counter and prescription drugs were subject to price controls and new restrictions were enacted which curtailed our ability to promote in Hangzhou where most of our pharmacies are located. Nevertheless, we plan to continue opening new stores in the coming fiscal year. During the three months ended March 31, 2012, the Company opened two pharmacies, including at premium locations designed to meet the needs of more affluent customers. As of June 26, 2012, the Company operated 64 retail pharmacy locations. In light of the challenges we are facing, however, we have pushed forward on our vertical integration strategy in order to reduce our reliance on retail pharmacy sales, starting with our acquisition of Zhejiang Jiuxin Medicine Co., Ltd., a wholesale distributor, … Continue reading

Posted in Wholesale Pharmacy | Comments Off on China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2012 Earnings Results and Schedules Conference Call for July 3, 2012

Murder trial told of drugs binge

Posted: Published on July 2nd, 2012

2 July 2012 Last updated at 11:17 ET A murder accused has told a jury he remembered little of the night he was alleged to have killed his best friend after an all-day drink and drug binge. Derek Kinghorn, 44, said he only became aware of anything untoward when he felt blood on his face from a head wound. He remembered drinking 10 cans of beer and smoking several cannabis joints earlier in the day. Mr Kinghorn denies murdering Brian Mair and assaulting Amy Michaels in his Hawick home in November last year. He told the High Court in Livingston that he and Mr Mair had been playing Playstation games and drinking and taking drugs since 10:00 on the day in question. Just before 19:00 Mr Kinghorn phoned a dealer to have more drugs delivered. He claimed the large kitchen knife, identified as the murder weapon, would have been brought into the room to divide up a lump of cannabis resin although he could not remember this happening. Mr Kinghorn said he had no memory of going out drinking at The Imperial Bar in Hawick with Mr Mair after the drugs had been delivered to his house. He said he … Continue reading

Posted in Drugs | Comments Off on Murder trial told of drugs binge

A Glut of Obesity Drugs?

Posted: Published on July 2nd, 2012

On June 27, the FDA approved the first new weight-loss drug in 13 years, Arenas lorcaserin (Belviq). The track record for anti-obesity drugs has not been very goodeach has been withdrawn from the market, after approval, due to safety concerns. Why was this drug approved? How long will this one last before being yanked for adverse events? Lets look at the background and track record of lorcaserins predecessors. Perspective on the need for weight loss drugs Why the brouhaha over Arenas new drug? According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese, defined as having a Body-Mass Index (BMI) of > 35. In the U.S. alone, 78 million U.S. adults are obese; another 34% of adults are overweight > 30. So 70% of U.S. adults have a problem with weight. Worldwide, CDC estimates 500 million are currently affected. Overweight and obesity constitute the second leading cause of preventable death, after smoking, resulting in an estimated 300,000 deaths per year. The number of obese is expected to rise to 42% by 2030, with an additional 11% prevalence of severe obesity (BMI >40, or ~80+ lbs overweight). In 2000, consumers spent … Continue reading

Posted in Drugs | Comments Off on A Glut of Obesity Drugs?

2000-plus schoolkids caught with drugs

Posted: Published on July 2nd, 2012

Students were caught with drugs in 2173 incidents at school last year and the youngest child to be stood down was in year 3. But the figure is the lowest in three years, according to preliminary data. Last year, there were 1324 stand-downs and 849 suspensions in New Zealand schools for drug-related behaviour (including substance abuse), according to figures released to the Herald. The Ministry of Education said the data was still being updated by schools and so could not be compared with other years, but previous figures have quoted there being 2441 drug incidents in 2009 and 2690 in 2010. A year 3 student - aged between 7 and 8 - was stood down in the Manawatu-Wanganui region. The youngest to be suspended were two year 5 students - aged between 9 and 10 - in Gisborne and Wellington. Gisborne had the highest number of incidents per capita where students were caught with drugs, with a total of 77 suspensions and stand-downs from a roll of 9353. A stand-down is the removal of a learner for a period of up to five days, with the decision made by the principal. A suspension is the formal removal of a student … Continue reading

Posted in Drugs | Comments Off on 2000-plus schoolkids caught with drugs

SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan – Video

Posted: Published on July 2nd, 2012

02-07-2012 09:43 State of the Nation is a nightly newscast anchored by award-winning broadcast journalist, Jessica Soho. It airs Mondays to Fridays at 9:00 PM (PHL Time) on GMA News TV Channel 11. For more videos from State of the Nation, visit fthenation. See the rest here: SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan - Video … Continue reading

Comments Off on SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan – Video

Protalix BioTherapeutics Announces New Clinical Data on taliglucerase alfa Presented at the 10th Annual European …

Posted: Published on July 2nd, 2012

CARMIEL, Israel, July 2, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (PLX) (PLX) announced today that new clinical data on taliglucerase alfa was presented at the 10th Annual European Working Group on Gaucher Disease Meeting that took place June 28-30 in Paris, France. Taliglucerase alfa is approved in the United States as an enzyme replacement therapy for the treatment of adults with type 1 Gaucher disease. Laura van Dussen, M.D., of the Academic Medical Center, University of Amsterdam, presented long-term bone marrow responses in Gaucher patients from the Company's pivotal and extension trials. Bone marrow imaging can be used as an important indicator for determining bone risk potential for Gaucher patients. Bone marrow fat fractions of eight naive patients from the pivotal and extension trials who were treated with taliglucerase alfa for at least 36 months, and 15 untreated Gaucher patients, were evaluated using Quantitative Chemical Shift Imaging (QCSI) MRI. At 36 months, the patients treated with taliglucerase alfa demonstrated a significant improvement in fat fraction from baseline (p-value = 0.012 after 36 months of follow-up). The range of absolute fat fraction values was between 0.19% and 0.42%, which corresponds to a mean change of 92% from baseline of fat … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Protalix BioTherapeutics Announces New Clinical Data on taliglucerase alfa Presented at the 10th Annual European …

Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart …

Posted: Published on July 2nd, 2012

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), announced today interim one-year results from its groundbreaking clinical trial evaluating Prochymal (remestemcel-L) for the treatment of patients experiencing first-time acute myocardial infarction. The trial is the largest study of allogeneic or "off-the-shelf" stem cells ever conducted in heart attack patients. A total of 220 patients were given a single infusion of either Prochymal or placebo through a standard intravenous line within seven days of an acute heart attack. Cardiac MRI assessments were conducted for six months following infarct to evaluate cardiac remodeling. Patients receiving Prochymal had significantly less cardiac hypertrophy, as measured by cardiac MRI, compared to patients receiving placebo (p … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart …

ACT Announces Second Patient with Stargardt’s Disease Treated in EU Clinical Trial

Posted: Published on July 2nd, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the second patient in its Phase 1/2 clinical trial for Stargardts macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, June 29 at Moorfields Eye Hospital in London, the same site as the first patient treatment in January, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The procedure was successfully performed without any complications. ACT and Moorfields Eye Hospital recently received clearance from the Data and Safety Monitoring Board (DSMB) to treat the final two patients in the first cohort of this clinical trial. We are very pleased to continue our forward momentum with both our U.S. trials and our European trial, commented Gary Rabin, chairman and CEO. It was less than a month ago that we received DSMB approval to treat the second and third patients in our E.U. trial, and it is very gratifying to have already completed dosing of the second. It is a pleasure to be … Continue reading

Posted in Stem Cell Human Trials | Comments Off on ACT Announces Second Patient with Stargardt’s Disease Treated in EU Clinical Trial

Researchers Block Pathway to Cancer Cell Replication

Posted: Published on July 2nd, 2012

NOTCH1 Signaling Promotes T-Cell Acute Lymphoblastic Leukemia-Initiating Cell Regeneration Newswise Research suggests that patients with leukemia sometimes relapse because standard chemotherapy fails to kill the self-renewing leukemia initiating cells, often referred to as cancer stem cells. In such cancers, the cells lie dormant for a time, only to later begin cloning, resulting in a return and metastasis of the disease. One such type of cancer is called pediatric T cell acute lymphoblastic leukemia, or T-ALL, often found in children, who have few treatment options beyond chemotherapy. A team of researchers led by Catriona H. M. Jamieson, MD, PhD, associate professor of medicine at the University of California, San Diego School of Medicine and Director of Stem Cell Research at UC San Diego Moores Cancer Center studied these cells in mouse models that had been transplanted with human leukemia cells. They discovered that the leukemia initiating cells which clone, or replicate, themselves most robustly activate the NOTCH1 pathway, usually in the context of a mutation. Earlier studies showed that as many as half of patients with T-ALL have mutations in the NOTCH1 pathway an evolutionarily conserved developmental pathway used during differentiation of many cell and tissue types. The new study shows … Continue reading

Comments Off on Researchers Block Pathway to Cancer Cell Replication

Page 6,712«..1020..6,7116,7126,7136,714..6,7206,730..»